期刊
JOURNAL OF CONTROLLED RELEASE
卷 268, 期 -, 页码 57-71出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2017.09.025
关键词
Peptides; Proteins; Insulin; In situ perfusion; In vivo; Macromolecules
资金
- Innovative Medicines Initiative Joint Undertaking from European Union's Seventh Framework Programme [115363]
- EFPIA
- Danish Research Council for Technology and Production (FTP) [DFF-4004-00120B]
- Danmarks Grundforskningsfonds [DNRF122]
- Villum Fonden [00009301] Funding Source: researchfish
Biopharmaceuticals are increasingly important for patients and the pharmaceutical industry due to their ability to treat and, in some cases, even cure chronic and potentially life-threatening diseases. Most biopharmaceuticals are administered by injection, but intensive focus on development of systems for oral delivery of biopharmaceuticals may result in new treatment modalities to increase the patient compliance and reduce product cost. In the preclinical development phase, use of experimental animal models is essential for evaluation of new formulation designs. In general, the limited oral bioavailability of biopharmaceuticals, of just a few percent, is expected, and therefore, the animal models and the experimental settings must be chosen with utmost care. More knowledge and focus on this topic is highly needed, despite experience from the numerous studies evaluating animal models for oral drug delivery of small molecule drugs. This review highlights and discusses pros and cons of the most currently used animal models and settings. Additionally, it also looks into the influence of anesthetics and sampling methods for evaluation of drug delivery systems for oral delivery of biopharmaceuticals primarily with examples on insulin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据